WO2026082894A1 - Conjugué anticorps-médicament ceacam5 destiné à être utilisé dans le traitement du cancer - Google Patents

Conjugué anticorps-médicament ceacam5 destiné à être utilisé dans le traitement du cancer

Info

Publication number
WO2026082894A1
WO2026082894A1 PCT/EP2025/079953 EP2025079953W WO2026082894A1 WO 2026082894 A1 WO2026082894 A1 WO 2026082894A1 EP 2025079953 W EP2025079953 W EP 2025079953W WO 2026082894 A1 WO2026082894 A1 WO 2026082894A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
ceacam5
administered
dose
drug conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/079953
Other languages
English (en)
Inventor
Samira BENSFIA
Mustapha CHADJAA
Phillip Dennis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of WO2026082894A1 publication Critical patent/WO2026082894A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des méthodes pour le traitement de cancers qui expriment CEACAM5. Certains aspects de la divulgation concernent la monothérapie avec des immunoconjugués comprenant un anticorps anti-CEACAM5. D'autres aspects de l'invention concernent des polythérapies comprenant des immunoconjugués comprenant un anticorps anti-CEACAM5 et un inhibiteur métabolique nucléosidique. Les compositions décrites sont utilisées pour traiter le cancer du pancréas.
PCT/EP2025/079953 2024-10-17 2025-10-16 Conjugué anticorps-médicament ceacam5 destiné à être utilisé dans le traitement du cancer Pending WO2026082894A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24306725.3 2024-10-17
EP24306725 2024-10-17

Publications (1)

Publication Number Publication Date
WO2026082894A1 true WO2026082894A1 (fr) 2026-04-23

Family

ID=93607904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/079953 Pending WO2026082894A1 (fr) 2024-10-17 2025-10-16 Conjugué anticorps-médicament ceacam5 destiné à être utilisé dans le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2026082894A1 (fr)

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
WO1981001145A1 (fr) 1979-10-18 1981-04-30 Univ Illinois Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
US4294757A (en) 1979-01-31 1981-10-13 Takeda Chemical Industries, Ltd 20-O-Acylmaytansinoids
US4301144A (en) 1979-07-11 1981-11-17 Ajinomoto Company, Incorporated Blood substitute containing modified hemoglobin
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4322348A (en) 1979-06-05 1982-03-30 Takeda Chemical Industries, Ltd. Maytansinoids
US4331598A (en) 1979-09-19 1982-05-25 Takeda Chemical Industries, Ltd. Maytansinoids
US4362663A (en) 1979-09-21 1982-12-07 Takeda Chemical Industries, Ltd. Maytansinoid compound
US4364866A (en) 1979-09-21 1982-12-21 Takeda Chemical Industries, Ltd. Maytansinoids
US4371533A (en) 1980-10-08 1983-02-01 Takeda Chemical Industries, Ltd. 4,5-Deoxymaytansinoids, their use and pharmaceutical compositions thereof
US4424219A (en) 1981-05-20 1984-01-03 Takeda Chemical Industries, Ltd. 9-Thiomaytansinoids and their pharmaceutical compositions and use
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4670417A (en) 1985-06-19 1987-06-02 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987005330A1 (fr) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Procede pour ameliorer la stabilite des glycoproteines
WO1988007378A1 (fr) 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Amelioration apportees a des systemes d'administration de medicaments
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1994011026A2 (fr) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Application therapeutique d'anticorps chimeriques et radio-marques contre l'antigene a differentiation restreinte des lymphocytes b humains pour le traitement du lymphome des cellules b
US5428176A (en) 1994-04-14 1995-06-27 Eli Lilly And Company Process for preparing 2,2-difluoroketene silyl O,S-acetals and α,α-difluoro-β-silyloxy-1,3-dioxolane-4-propanoic acid O,S-esters
US5464826A (en) 1984-12-04 1995-11-07 Eli Lilly And Company Method of treating tumors in mammals with 2',2'-difluoronucleosides
US5475092A (en) 1992-03-25 1995-12-12 Immunogen Inc. Cell binding agent conjugates of analogues and derivatives of CC-1065
US5756775A (en) 1995-12-13 1998-05-26 Eli Lilly And Company Process to make α,α-difluoro-β-hydroxyl thiol esters
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
WO2004091668A1 (fr) 2003-04-15 2004-10-28 Algeta As Thorium 227 utilisable en radiotherapie pour traiter une maladie des tissus mous
WO2008010101A2 (fr) 2006-07-18 2008-01-24 Sanofi-Aventis Anticorps antagoniste destiné au traitement du cancer
WO2014079886A1 (fr) 2012-11-20 2014-05-30 Sanofi Anticorps anti-ceacam5 et leurs utilisations
WO2021214222A1 (fr) * 2020-04-24 2021-10-28 Sanofi Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5, de la trifluridine et du tipiracil

Patent Citations (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4361650A (en) 1978-03-24 1982-11-30 Takeda Chemical Industries, Ltd. Fermentation process of preparing demethyl maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
US4294757A (en) 1979-01-31 1981-10-13 Takeda Chemical Industries, Ltd 20-O-Acylmaytansinoids
US4322348A (en) 1979-06-05 1982-03-30 Takeda Chemical Industries, Ltd. Maytansinoids
US4301144A (en) 1979-07-11 1981-11-17 Ajinomoto Company, Incorporated Blood substitute containing modified hemoglobin
US4331598A (en) 1979-09-19 1982-05-25 Takeda Chemical Industries, Ltd. Maytansinoids
US4362663A (en) 1979-09-21 1982-12-07 Takeda Chemical Industries, Ltd. Maytansinoid compound
US4364866A (en) 1979-09-21 1982-12-21 Takeda Chemical Industries, Ltd. Maytansinoids
WO1981001145A1 (fr) 1979-10-18 1981-04-30 Univ Illinois Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
US4371533A (en) 1980-10-08 1983-02-01 Takeda Chemical Industries, Ltd. 4,5-Deoxymaytansinoids, their use and pharmaceutical compositions thereof
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4424219A (en) 1981-05-20 1984-01-03 Takeda Chemical Industries, Ltd. 9-Thiomaytansinoids and their pharmaceutical compositions and use
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4808614A (en) 1983-03-10 1989-02-28 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5464826A (en) 1984-12-04 1995-11-07 Eli Lilly And Company Method of treating tumors in mammals with 2',2'-difluoronucleosides
US4670417A (en) 1985-06-19 1987-06-02 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987005330A1 (fr) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Procede pour ameliorer la stabilite des glycoproteines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988007378A1 (fr) 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Amelioration apportees a des systemes d'administration de medicaments
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5846545A (en) 1992-03-25 1998-12-08 Immunogen, Inc. Targeted delivery of cyclopropylbenzindole-containing cytotoxic drugs
US5475092A (en) 1992-03-25 1995-12-12 Immunogen Inc. Cell binding agent conjugates of analogues and derivatives of CC-1065
US5585499A (en) 1992-03-25 1996-12-17 Immunogen Inc. Cyclopropylbenzindole-containing cytotoxic drugs
WO1994011026A2 (fr) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Application therapeutique d'anticorps chimeriques et radio-marques contre l'antigene a differentiation restreinte des lymphocytes b humains pour le traitement du lymphome des cellules b
US5428176A (en) 1994-04-14 1995-06-27 Eli Lilly And Company Process for preparing 2,2-difluoroketene silyl O,S-acetals and α,α-difluoro-β-silyloxy-1,3-dioxolane-4-propanoic acid O,S-esters
US5756775A (en) 1995-12-13 1998-05-26 Eli Lilly And Company Process to make α,α-difluoro-β-hydroxyl thiol esters
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
WO2004091668A1 (fr) 2003-04-15 2004-10-28 Algeta As Thorium 227 utilisable en radiotherapie pour traiter une maladie des tissus mous
WO2008010101A2 (fr) 2006-07-18 2008-01-24 Sanofi-Aventis Anticorps antagoniste destiné au traitement du cancer
WO2014079886A1 (fr) 2012-11-20 2014-05-30 Sanofi Anticorps anti-ceacam5 et leurs utilisations
WO2021214222A1 (fr) * 2020-04-24 2021-10-28 Sanofi Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5, de la trifluridine et du tipiracil

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
"Cancer facts and figures", AMERICAN CANCER SOCIETY, 21 July 2022 (2022-07-21), Retrieved from the Internet <URL:https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2011.html>
"GenBank", Database accession no. AAA51967.1
"NCCN Clinical Practice Guidelines in Oncology Pancreatic adenocarcinoma", NATIONAL COMPREHENSIVE CANCER NETWORK, 21 July 2022 (2022-07-21), Retrieved from the Internet <URL:https://www.ncen.org/professionals/physician_gls/pdf/pancreatic.pdf>
ALMAGROFRANSSON, FRONT BIOSCI., vol. 13, 2008, pages 1619 - 1633
AMERICAN CANCER SOCIETY. CANCER FACTS AND FIGURES, 21 July 2022 (2022-07-21), Retrieved from the Internet <URL:https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2013/cancer-facts-and-figures-special-section-2013.pdf>
ANGAL ET AL., MOLECULAR IMMUNOLOGY, vol. 30, 1993, pages 105
ANONYMOUS: "Clinical Trial Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01) | NCT04659603 | ClinicalTrials.gov", 13 August 2024 (2024-08-13), XP093257617, Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT04659603?intr=tusamitamab%20ravtansine&rank=4&tab=history&a=23#version-content-panel> *
ANONYMOUS: "NCT03324113 Evaluation of SAR408701 in Combination With Other Anti-tumor Drug in Japanese Patients With Advanced Malignant Solid Tumors", 15 January 2019 (2019-01-15), XP055737578, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03324113?V_9=View> [retrieved on 20201007] *
CONROY TDESSEIGNE FYCHOU MBOUCHE OGUIMBAUD RBECOUARN Y ET AL.: "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N ENGL J MED., vol. 364, no. 19, 2011, pages 1817 - 25
CROMWELL ET AL., AAPS JOURNAL, vol. 8, no. 3, 2006, pages E572 - E579
EBRAHIMMNEJAD ET AL., EXP CELL RES, vol. 260, 2000, pages 365
EISENHAUER EATHERASSE PBOGAERTS J SCHWARTZ LHSARGENT DFORD R ET AL.: "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1", EUR J CANCER, vol. 525, no. 2, 2009, pages 228 - 47
GOLD PFREEDMAN SO: "Specific carcinoembryonic antigens of the human digestive system", J EXP MED., vol. 122, no. 3, 1965, pages 467 - 81
GOLDFREEDMAN, J EXP MED, vol. 121, 1965, pages 439
HAMMARSTROM ET AL.: "Tumor Markers, Physiology, Pathobiology, Technology and Clinical Applications", 2002, AACC PRESS, pages: 375
HAMMARSTROM S.: "The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues", SEMIN CANCER BIOL., vol. 9, no. 2, 1999, pages 1035 - 1038
HESKETH PJKRIS MGBASCH EBOHLKE KBARBOUR SYCLARK-SNOW RA ET AL.: "Antiemetics: ASCO Guideline Update", J CLIN ONCOL., vol. 38, no. 24, 2020, pages 2782 - 97
JESPERS ET AL., BIOTECHNOLOGY, vol. 12, 1994, pages 899
MITA NIWASHITA TUEMURA SYOSHIDA KIWASA YANDO N ET AL.: "Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure", J CLIN MED., vol. 8, no. 6, 29 May 2019 (2019-05-29), pages 761
OKEN MMCREECH RHTORMEY DCHORTON JDAVIS TEMCFADDEN ET ET AL.: "Toxicity and response criteria of the eastern cooperative oncology group", AM J CLIN ONCOL., vol. 5, no. 6, 1982, pages 649 - 55
SHARKEY ET AL., CANCER RESEARCH, vol. 50, 1990, pages 2823
SMITH TJBOHLKE KLYMAN GHCARSON KRCRAWFORD JCROSS SJ ET AL.: "Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update", J CLIN ONCOL., vol. 33, no. 28, 2015, pages 3199 - 212
STRICKLAND ET AL., J PATHOL, vol. 218, 2009, pages 380
TABERNERO JOSEP ET AL: "Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens", CANCER RESEARCH COMMUNICATIONS, vol. 3, no. 8, 28 August 2023 (2023-08-28), pages 1662 - 1671, XP093259496, ISSN: 2767-9764, DOI: 10.1158/2767-9764.CRC-23-0284 *
TAYLOR ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295
THOMPSON JA.: "Molecular cloning and expression of carcinoembryonic antigen family members", TUMOR BIOL., vol. 16, no. 1, 1995, pages 10 - 6
VON HOFF DDERVIN TARENA FPCHIOREAN EGINFANTE JMOORE M ET AL.: "Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine", N ENGL J MED., vol. 369, no. 18, 2013, pages 1691 - 703
WALTER ET AL., ANAL. BIOCHEM., vol. 212, no. 2, 1993, pages 469 - 480
WANGGOSH, J. MEMBRANE SCI., vol. 318, no. 2254086-60-5, 2008, pages 311 - 316
ZHAO ET AL., J IMMUNOL METHODS, vol. 293, 2004, pages 207

Similar Documents

Publication Publication Date Title
US20250154250A1 (en) Ceacam5 adc-anti-pd1/pd-l1 combination therapy
JP7597718B2 (ja) 肺がんを処置するための抗ｃｅａｃａｍ５イムノコンジュゲートの使用
US20250041434A1 (en) Cea assay for patient selection in cancer therapy
EP3762032A1 (fr) Conjugués de médicament et d&#39;anticorps anti-facteur tissulaire, et leur utilisation dans le traitement du cancer
AU2019321442A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
WO2019217457A1 (fr) Méthodes de traitement du cancer au moyen d&#39;une combinaison d&#39;un conjugué de medicament anticorps anti-pd-1 et anticorps anti-facteur tissulaire
EP3693023A1 (fr) Utilisation d&#39;immuno-conjugués anti-ceacam5 pour le traitement du cancer du poumon
CN115052890A (zh) 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合以治疗癌症的方法
CN120826244A (zh) 含有抗ceacam5抗体-药物缀合物、抗vegfr-2抗体和抗pd1/pd-l1抗体的抗肿瘤组合
WO2025169012A1 (fr) Méthodes de traitement de cancers exprimant ceacam5
WO2026082894A1 (fr) Conjugué anticorps-médicament ceacam5 destiné à être utilisé dans le traitement du cancer
CN115697400A (zh) 抗cd30抗体-药物缀合物及其用于治疗非霍奇金淋巴瘤的用途
RU2828374C2 (ru) Применение иммуноконъюгатов к ceacam5 для лечения рака легкого
CN118574639A (zh) Ceacam5 adc-抗pd1/pd-l1组合疗法
WO2025208105A1 (fr) Constructions, compositions et méthodes de traitement d&#39;un variant d&#39;épissage à extra domaine b de maladies et de troubles exprimant la fibronectine
CN118613278A (zh) 癌症疗法中用于患者选择的cea测定
EA048671B1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака